• 20048 Citations
  • 80 h-Index
1989 …2019
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

External positions

Pathology

Fingerprint Dive into the research topics where Yang-Xin Fu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 22 Similar Profiles
Lymphotoxin-alpha Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Dendritic Cells Medicine & Life Sciences
B-Lymphocytes Medicine & Life Sciences
Immunity Medicine & Life Sciences
Light Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2019

A bioactive mammalian disaccharide associated with autoimmunity activates STING-TBK1-dependent immune response

Fermaintt, C. S., Sano, K., Liu, Z., Ishii, N., Seino, J., Dobbs, N., Suzuki, T., Fu, Y-X., Lehrman, M. A., Matsuo, I. & Yan, N., Dec 1 2019, In : Nature communications. 10, 1, 2377.

Research output: Contribution to journalArticle

Open Access
Disaccharides
activity (biology)
Autoimmunity
Autoimmune Diseases
Polysaccharides

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Sun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., Xu, H., Shi, J., Wang, F., Fu, Y-X. & Peng, H., Dec 1 2019, In : Nature communications. 10, 1, 3874.

Research output: Contribution to journalArticle

Open Access
T-cells
Interleukin-2
Tumors
therapy
tumors

Degradation of CTLA-4 balances toxicity and efficacy

Ren, Z. & Fu, Y-X., Jan 1 2019, (Accepted/In press) In : Science Bulletin.

Research output: Contribution to journalComment/debate

Erratum: Targeting CD137 enhances the efficacy of cetuximab(J Clin Invest. (2019)129:6 (2595-2595) DOI: 10.1172/JCI129689)

Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, A., Hebb, J., Chester, C., Waller, E., Ostashko, A., Weng, W. K., Chen, L., Czerwinski, D. & 3 others, Fu, Y-X., Sunwoo, J. & Levy, R., Jun 3 2019, In : Journal of Clinical Investigation. 129, 6, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Information Storage and Retrieval
Medicine
Cetuximab

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Liu, Z., Han, C., Dong, C., Shen, A., Hsu, E., Ren, Z., Lu, C., Liu, L., Zhang, A., Timmerman, C., Pu, Y., Wang, Y., Chen, M., Qiao, J. & Fu, Y-X., Aug 9 2019, In : Science Immunology. 4, 38

Research output: Contribution to journalArticle

Adaptive Immunity
Epidermal Growth Factor Receptor
Innate Immunity
Protein-Tyrosine Kinases
Recurrence